Castle Biosciences Licenses BAP1 Gene from Wash U. for Melanoma Metastasis Detection | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Castle Biosciences today announced it has licensed the BAP1 gene from Washington University in St. Louis for detecting metastasis in patients with melanoma.

The Friendswood, Texas-based firm has begun validation studies for use of the technology in both uveal melanoma, or ocular melanoma, and cutaneous melanoma and plans to incorporate the gene into its DecisionDx-UM assay. It also has an option for use of the gene for other cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.